Stanford professor Russ Altman emphasizes that AI is opening new opportunities to understand how medicines interact with specific proteins, and build more highly customized therapies. He points to DeepMind’s AlphaFold 2 deep learning system as a particularly powerful new tool for re-envisioning how drugs are discovered and designed.

Video clips from: Principled Engineering: AI and Drug Development [Entire Talk]

3 minutes

Where is AI-Driven Bioengineering Headed Next?

Watch now

9 minutes

Innovation-Driven Engagement with Regulators

Watch now

3 minutes

Ethical Science is Better Science

Watch now

3 minutes

Ethical Guardrails for AI in Drug Development

Watch now